Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol 2011; 37: 466–472.

Published: 27th September 2011

Authors: Zhang X-L, Shi H-J, Cui S-Z, Tang Y-Q, Ba M-C.

Conclusion

Two different chemotherapy regimens were compared in 80 patients. The addition of oxaliplatin improved recurrence-free (30 versus 16 months, P<0.05) and overall survival (36 versus 28 months, P<0.05), but 19 per cent rate of the patients developed peripheral neuropathy.

Pubmed Link

Your comments

0 Comments